A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects
Status:
Completed
Trial end date:
2018-04-24
Target enrollment:
Participant gender:
Summary
A phase 1 open-label, single-dose study to evaluate the pharmacokinetics (PK), safety,
tolerability and immunogenicity of MEDI0382 in subjects with renal impairment.